转自：证券时报 人民财讯8月12日电，蓝思科技(300433)近日在机构调研中表示，目前公司正与合作伙伴一道，配合客 户开发下一代盖板玻璃，新的玻璃原片将应用创新配方，使盖板结构以及整机能够带来更加丰富的性 能，以及更好的用户体验。 ...

证券日报网讯联创电子（002036）8月12日在互动平台回答投资者提问时表示，公司会积极跟踪与研究 客户需求，基于自身在精密制造和智能制造方面的能力，开发有市场竞争力的产品。 ...

Group 1 - Kuaishou (快手) is expected to achieve net profits of 177 billion, 210 billion, and 244 billion yuan in 2025-2027, driven by AI business differentiation and commercialization breakthroughs, receiving a "buy" rating from Western Securities [2] - Hutchison China MediTech (和黄医药) has seen its core product revenues fall below expectations, leading to a downward revision of its annual tumor revenue guidance, but maintains a "buy" rating due to strong cash reserves and potential for external asset acquisition [3] - Hua Hong Semiconductor (华虹半导体) reported better-than-expected gross margins in Q2 2025 and has positive revenue and margin guidance for Q3 2025, supported by stable demand growth and domestic order recovery, receiving an "outperform" rating from CICC [4][5] Group 2 - China General Nuclear Power (中广核电力) has its rating upgraded to "outperform" with a target price of 3.7 HKD, as new sales agreements are expected to have a minimal cost impact, and the outlook for projects is clear [6] - Kingdee International (金蝶国际) reported mid-term results in line with expectations, with AI contract scale exceeding forecasts, leading to adjusted revenue predictions for 2025-2027, maintaining a "buy" rating [7] - Q Technology (丘钛科技) is benefiting from strong IoT demand, with an upward adjustment of the target price to 17.9 HKD, as the momentum is expected to continue driving profit growth into 2026 [8] Group 3 - Conant Optical (康耐特光学) is projected to achieve a compound annual growth rate of 26% in EPS from 2025-2026, supported by its R&D capabilities and customer base, receiving an "outperform" rating [9] - Semiconductor Manufacturing International Corporation (中芯国际) has a neutral rating with a target price adjustment to 47 HKD, as average chip prices are expected to be higher in Q3 compared to Q2, with revenue forecasts for 2025 and 2026 at 9.29 billion and 11 billion USD respectively [10] - Anjoy Foods (安井食品) is recognized as a leader in the frozen food industry in China, with a projected market share of 6.6% in 2024, and is expected to maintain its market position due to operational excellence and product development experience, receiving a "buy" rating [11]

今日东山精密（002384）涨6.39%，收盘报55.64元。 东山精密（002384）个股概况： | 财务摘要 | 东山精密2025年—季报显示，公司主营收入86.02亿元，同比上升11.07%； 归 母净利润4.56亿元，同比上升57.55%；扣非净利润3.97亿元，同比上升51.8 | | --- | --- | | | 3%;负债率58.26%,投资收益-575.65万元,财务费用694.13万元,毛利率1 4.13%。 | | 机构评级 | 该股最近90天内共有11家机构给出评级，买入评级11家；过去90天内机构目 标均价为45.84。 | | 融资融券 | 近3个月融资净流入1676.28万,融资余额增加;融券净流出1327.3万,融券 余额减少。 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 2025年6月16日，民生证券研究员方竞,宋晓东发布了对东山精密的研报《事件点评：算力追光者，东山 精密收购索尔思光电》，该研报对东山精密给出"买入"评级。研报中预计公司25-27年归母净利润为 26.84/36.40/46 ...

Core Viewpoint - The recent announcement of subscription limits for the China Europe Medical Innovation Fund managed by Ge Lan highlights the strong rebound in the innovative drug sector, with significant year-to-date gains in related funds and stocks [1][2]. Fund Performance and Subscription Limits - The China Europe Medical Innovation Fund has seen a year-to-date return exceeding 60%, with its scale increasing to 8.1 billion yuan by the end of Q2 [1][4]. - Over 30 actively managed equity funds have announced subscription limits since July, indicating a cautious approach by fund managers in response to rapid inflows [2][7]. - The China Europe Medical Innovation Fund's performance is notable, but it has not recovered from significant losses over the past three years, with a decline of 9.62% [2][6]. Market Trends and Fund Management - The strong performance of the innovative drug sector is reflected in the China Securities Index's pharmaceutical and biotechnology index, which has risen over 20% in the past year [5]. - The subscription limits are intended to stabilize fund operations and protect the interests of existing investors, serving as a buffer against excessive short-term inflows [2][3]. - Other funds managed by prominent managers, such as the China Europe Digital Economy Fund and the China Europe Science and Technology Innovation Fund, have also implemented subscription limits to manage inflows effectively [2][3]. Fund Composition and Strategy - The China Europe Medical Innovation Fund has a heavy allocation in the pharmaceutical and biotechnology sector, with 91.62% of its holdings in this area, primarily in stocks like 3SBio, which has seen a nearly 400% increase this year [5][6]. - The fund's previous subscription limit was set at 5 million yuan per day, indicating a history of managing inflows carefully [5][6]. Broader Market Context - The recent trend of subscription limits among high-performing funds reflects a broader strategy to maintain fund performance and manage investor expectations amid a rising equity market [7][10]. - The market outlook suggests potential structural characteristics in A-shares, with expectations of continued recovery in risk appetite due to easing monetary policies and reduced global trade tensions [12].

Core Viewpoint - The U.S. government announced "reciprocal tariffs" on global trade partners, with significant rates imposed on China, Vietnam, Thailand, and India, prompting various responses from over 30 listed companies in China regarding the impact on their operations [1] Group 1: Impact on Companies - Companies with high export revenue to the U.S. expressed significant concerns about the new tariffs, such as Fuling Co., which reported that 65.73% and 65.74% of its revenue came from U.S. sales in 2023 and the first half of 2024, respectively [2] - Other companies, like Betta Pharmaceuticals, noted that their products were exempt from the new tariff categories, indicating a varied impact across sectors [3] - Companies such as ST Hongyang and Guangxin Materials reported minimal exposure to the U.S. market, suggesting limited effects from the tariffs [4] Group 2: Preparedness and Strategies - Some companies, including Mindray Medical, had proactively prepared for tariff impacts by stockpiling products in the U.S. prior to the tariff implementation, resulting in no immediate effect on their sales [5] - Daotong Technology indicated that it had already sought manufacturing locations in low-tariff regions to mitigate the impact of the new tariffs [6] - Companies like Huayi Group and Bowei Alloy are implementing strategies to reduce the impact of tariffs, including establishing production facilities in the U.S. and optimizing their supply chains [7] Group 3: Ongoing Monitoring and Adaptation - Many companies are actively monitoring the situation and discussing strategies with clients to adapt to the evolving tariff landscape, with some expressing uncertainty about how the tariffs will be implemented [8] - Yiyi Co. emphasized the need for ongoing communication with clients and exploring new international markets to enhance resilience against tariff impacts [8] - Xinbao Co. highlighted its global presence, with 30% to 40% of its export sales coming from North America, and is committed to closely monitoring tariff changes to ensure stable operations [9]

"近期，在一系列政策'组合拳'稳定市场预期后，上市公司回购或主要股东增持力度有望提升，这 将进一步提振市场信心，助力市场形成稳定运行的正向传递机制。"实用金融商学执行院长罗攀在接受 《证券日报》记者采访时表示。 自上市以来，工业富联持续通过"注销式回购+大手笔分红"的"组合拳"，加强对投资者的回报。 4月14日晚间，富士康工业互联网股份有限公司（以下简称"工业富联"）发布公告称，公司拟使用 不低于5亿元（含）且不超过10亿元（含）的自有资金，以集中竞价交易方式回购股份，回购价格不超 过20元每股，回购的股份将用于注销以减少注册资本。 公告显示，在回购股份价格不超过20元每股的条件下，若按照回购资金总额上限和下限测算，预计 可回购数量约为2500万股至5000万股，回购股份占公司目前总股本的0.1259%至0.2518%。回购期限为 自公司股东大会审议通过回购股份方案之日起不超过12个月。 工业富联表示，基于对公司未来发展前景的信心及对公司长期价值的认可，为维护广大股东利益， 增强投资者信心，在综合考虑公司财务状况以及未来的盈利能力的情况下，公司拟进行本次注销式回 购。 "注销式回购可使公司总股本减少，从而提高 ...

Group 1 - The Hang Seng Index rose by 0.09% during the midday close [1] - The Hang Seng Tech Index experienced a decline of 0.39% [1] - BYD Electronics saw an increase of over 4% [1] Group 2 - Kingdee International faced a significant drop of over 7% [1]

Group 1 - The core viewpoint of the article highlights that Huiju Technology (01729) has seen its stock price rise over 5%, reaching a historical high of 11.48 HKD, driven by strong sales orders in its data center segment [1] - The company expects a profit increase of approximately 50% to 60% for the six months ending June 30, 2025, compared to the mid-year report of 2024, primarily due to increased sales orders in the wire component division [1] - Luxshare Precision plans to issue H-shares for a listing in Hong Kong to deepen its global strategic layout, having acquired a 74.67% stake in Huiju Technology through its subsidiary [1] Group 2 - The trading volume for Huiju Technology reached 39.81 million HKD at the time of reporting, indicating strong market interest [1] - Huatai Securities anticipates that 19 stocks, including Huiju Technology, may be included in the Hong Kong Stock Connect in early September [1]

Group 1 - The core viewpoint of the article highlights that Huiju Technology (01729) has seen its stock price increase by over 5%, reaching a historical high of 11.48 HKD, with a current price of 11.47 HKD and a trading volume of 39.81 million HKD [1] - Huiju Technology announced an expected growth of approximately 50% to 60% in net profit for the six months ending June 30, 2025, compared to the mid-year report of 2024, primarily driven by increased sales orders in the data center segment of its wire components division [1] - Luxshare Precision (002475) plans to issue H-shares for a listing in Hong Kong to deepen its global strategic layout, having acquired Huiju Technology through its subsidiary in February 2022, holding 74.67% of Huiju's shares post-acquisition [1] Group 2 - Huatai Securities anticipates that 19 stocks, including Huiju Technology, may be included in the Hong Kong Stock Connect in early September [1]